AIMS: To compare the pharmacokinetics of oseltamivir and oseltamivir carboxylate in hepatically impaired patients and healthy subjects. METHODS: Hepatically impaired patients (n = 11) and healthy subjects (n = 11) were individually paired on the basis of gender, age (+/-10 years) and body weight (+/-20%) and administered a single dose of oseltamivir (75 mg). RESULTS: Oseltamivir and oseltamivir carboxylate C(max) were < or =6% and < or =19% lower, and their AUC(0,infinity) 33% higher and < or =19% lower, respectively, in hepatically impaired patients compared with healthy subjects. These changes are within the safety limits for the drug. CONCLUSIONS: The metabolism of oseltamivir is not compromised [corrected] in hepatically impaired patients. No dose adjustment is required in these patients when receiving oseltamivir.
AIMS: To compare the pharmacokinetics of oseltamivir and oseltamivir carboxylate in hepatically impairedpatients and healthy subjects. METHODS:Hepatically impairedpatients (n = 11) and healthy subjects (n = 11) were individually paired on the basis of gender, age (+/-10 years) and body weight (+/-20%) and administered a single dose of oseltamivir (75 mg). RESULTS:Oseltamivir and oseltamivir carboxylate C(max) were < or =6% and < or =19% lower, and their AUC(0,infinity) 33% higher and < or =19% lower, respectively, in hepatically impairedpatients compared with healthy subjects. These changes are within the safety limits for the drug. CONCLUSIONS: The metabolism of oseltamivir is not compromised [corrected] in hepatically impairedpatients. No dose adjustment is required in these patients when receiving oseltamivir.
Authors: J J Treanor; F G Hayden; P S Vrooman; R Barbarash; R Bettis; D Riff; S Singh; N Kinnersley; P Ward; R G Mills Journal: JAMA Date: 2000-02-23 Impact factor: 56.272
Authors: Niklas Lindegardh; Geraint R Davies; Tinh Hien Tran; Jeremy Farrar; Pratap Singhasivanon; Nicholas P J Day; Nicholas J White Journal: Antimicrob Agents Chemother Date: 2006-09 Impact factor: 5.191
Authors: Won-Young Kim; Gee Young Suh; Jin Won Huh; Sung-Han Kim; Min-ju Kim; Yun Seong Kim; Hye-Ryoun Kim; Yon Ju Ryu; Min Soo Han; Young Gwan Ko; Gyu Rak Chon; Kwan Ho Lee; Sang-Ho Choi; Sang-Bum Hong Journal: Antimicrob Agents Chemother Date: 2011-10-03 Impact factor: 5.191
Authors: Robert E Ariano; Daniel S Sitar; Sheryl A Zelenitsky; Ryan Zarychanski; Amarnath Pisipati; Stéphane Ahern; Salmaan Kanji; Jordi Rello; Anand Kumar Journal: CMAJ Date: 2010-02-16 Impact factor: 8.262
Authors: J G Coen van Hasselt; Marilee A Andrew; Mary F Hebert; Joel Tarning; Paolo Vicini; Donald R Mattison Journal: Br J Clin Pharmacol Date: 2012-12 Impact factor: 4.335